| pubmed-article:15196263 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0042164 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0004943 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0599028 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C1704666 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C1517892 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0008357 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C0208973 | lld:lifeskim |
| pubmed-article:15196263 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:15196263 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15196263 | pubmed:dateCreated | 2004-6-15 | lld:pubmed |
| pubmed-article:15196263 | pubmed:abstractText | Behcet's disease (BD) specific peptide (p336-351) was identified within the human 60 kD heat shock protein (HSP60). Oral p336-351 induced uveitis in rats which was prevented by oral tolerization with the peptide linked to recombinant cholera toxin B subunit (CTB). This strategy was adopted in a phase I/II clinical trial by oral administration of p336-351-CTB, 3 times weekly, followed by gradual withdrawal of all immunosuppressive drugs used to control the disease in 8 patients with BD. The patients were monitored by clinical and ophthalmological examination, as well as extensive immunological investigations. Oral administration of p336-351-CTB had no adverse effect and withdrawal of the immunosuppressive drugs showed no relapse of uveitis in 5 of 8 patients or 5 of 6 selected patients who were free of disease activity prior to initiating the tolerization regimen. After tolerization was discontinued, 3 of 5 patients remained free of relapsing uveitis for 10-18 months after cessation of all treatment. Control of uveitis and extra-ocular manifestations of BD was associated with a lack of peptide-specific CD4+ T cell proliferation, a decrease in expression of TH1 type cells (CCR5, CXCR3), IFN-gamma and TNF-alpha production, CCR7+ T cells and costimulatory molecules (CD40 and CD28), as compared with an increase in these parameters in patients in whom uveitis had relapsed. The efficacy of oral peptide-CTB tolerization will need to be confirmed in a phase III trial, but this novel strategy in humans might be applicable generally to autoimmune diseases in which specific antigens have been identified. | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15196263 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15196263 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15196263 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15196263 | pubmed:issn | 0009-9104 | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:HolmgrenJJ | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:MizushimaYY | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:LehnerTT | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:BergmeierL... | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:LundinSS | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:ShinnickTT | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:StanfordMM | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:LindbladMM | lld:pubmed |
| pubmed-article:15196263 | pubmed:author | pubmed-author:WhittallTT | lld:pubmed |
| pubmed-article:15196263 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15196263 | pubmed:volume | 137 | lld:pubmed |
| pubmed-article:15196263 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15196263 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15196263 | pubmed:pagination | 201-8 | lld:pubmed |
| pubmed-article:15196263 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:meshHeading | pubmed-meshheading:15196263... | lld:pubmed |
| pubmed-article:15196263 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15196263 | pubmed:articleTitle | Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. | lld:pubmed |
| pubmed-article:15196263 | pubmed:affiliation | Department of Ophthalmology, Guy's, King's and St. Thomas' School of Medicine and Dentistry, Guy's Hospital, London, UK. | lld:pubmed |
| pubmed-article:15196263 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15196263 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15196263 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15196263 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
